Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) major shareholder Marlio Charles Mosseri acquired 5,603 shares of the firm's stock in a transaction on Friday, June 20th. The shares were acquired at an average price of $7.99 per share, with a total value of $44,767.97. Following the completion of the purchase, the insider now owns 2,981,806 shares of the company's stock, valued at $23,824,629.94. This trade represents a 0.19% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Marlio Charles Mosseri also recently made the following trade(s):
- On Wednesday, June 18th, Marlio Charles Mosseri bought 28,043 shares of Nuvectis Pharma stock. The shares were acquired at an average price of $8.05 per share, for a total transaction of $225,746.15.
- On Tuesday, June 17th, Marlio Charles Mosseri purchased 5,399 shares of Nuvectis Pharma stock. The shares were acquired at an average cost of $8.11 per share, with a total value of $43,785.89.
- On Monday, May 12th, Marlio Charles Mosseri acquired 21,167 shares of Nuvectis Pharma stock. The stock was bought at an average cost of $8.11 per share, for a total transaction of $171,664.37.
- On Thursday, May 8th, Marlio Charles Mosseri bought 2,650 shares of Nuvectis Pharma stock. The stock was bought at an average price of $8.65 per share, with a total value of $22,922.50.
- On Tuesday, May 6th, Marlio Charles Mosseri purchased 12,444 shares of Nuvectis Pharma stock. The stock was bought at an average price of $8.59 per share, with a total value of $106,893.96.
Nuvectis Pharma Stock Performance
Shares of NVCT stock traded up $0.02 during mid-day trading on Tuesday, reaching $7.98. 71,667 shares of the company were exchanged, compared to its average volume of 128,990. The business's 50 day simple moving average is $9.25 and its 200 day simple moving average is $7.74. The company has a market capitalization of $166.70 million, a P/E ratio of -7.06 and a beta of -0.16. Nuvectis Pharma, Inc. has a fifty-two week low of $4.44 and a fifty-two week high of $11.80.
Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.03. On average, analysts forecast that Nuvectis Pharma, Inc. will post -1.01 EPS for the current year.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on the stock. Maxim Group initiated coverage on shares of Nuvectis Pharma in a research note on Wednesday, April 2nd. They set a "buy" rating and a $17.00 price objective on the stock. Wall Street Zen raised shares of Nuvectis Pharma from a "sell" rating to a "hold" rating in a research note on Saturday. Laidlaw started coverage on shares of Nuvectis Pharma in a report on Monday, March 17th. They issued a "buy" rating and a $19.00 price objective on the stock. Finally, HC Wainwright restated a "buy" rating and set a $15.00 target price (up from $11.00) on shares of Nuvectis Pharma in a research note on Wednesday, April 30th.
Read Our Latest Stock Analysis on NVCT
Institutional Trading of Nuvectis Pharma
Hedge funds and other institutional investors have recently bought and sold shares of the company. Iridian Asset Management LLC CT bought a new stake in shares of Nuvectis Pharma in the 1st quarter valued at approximately $2,481,000. Marshall Wace LLP lifted its stake in Nuvectis Pharma by 191.0% during the fourth quarter. Marshall Wace LLP now owns 124,571 shares of the company's stock worth $674,000 after purchasing an additional 81,757 shares during the last quarter. Goldman Sachs Group Inc. acquired a new position in Nuvectis Pharma in the first quarter worth $446,000. Jane Street Group LLC bought a new stake in Nuvectis Pharma during the first quarter valued at $413,000. Finally, Austin Wealth Management LLC acquired a new stake in shares of Nuvectis Pharma during the first quarter worth $393,000. 96.77% of the stock is owned by institutional investors.
Nuvectis Pharma Company Profile
(
Get Free Report)
Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nuvectis Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvectis Pharma wasn't on the list.
While Nuvectis Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
